|
PACE® Science PACE Biology Clinical Studies Scientific Literature Products |
Clinical Studies SANUWAVE Announces Positive Top-Line Data from its Pivotal Trial Investigating the Use of dermaPACE® for the Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcer SANUWAVE, Inc. is conducting a global, pivotal Investigational Device Exemption (IDE) clinical study of the dermaPACE® device for the treatment of diabetic foot ulcers. The purpose of this study is to compare the safety and effectiveness of the dermaPACE device to placebo application when administered in conjunction with standard treatments of diabetic foot ulcers. Placebo controlled, randomized, double blinded, prospective, multi-center trial Up to 280 patients Start date: September 2007 Primary Outcome Measures: The primary variable for effectiveness of the dermaPACE device will be assessed by comparing the incidence of complete wound closure of the dermaPACE and control groups 12 weeks post initial application. Secondary Outcome Measures: Time to wound closure, wound closure area and volume between active and control 12 weeks post initial application, subject pain assessment between active and control 24 weeks post initial application. Detailed Description: Shock wave devices, which utilize acoustic pressure waves, have been used for about 30 years in urology for lithotripsy. In the last decade this technology has gained FDA approval to treat chronic plantar fasciitis and lateral epicondylitis conditions that do not respond to conservative treatments (OssaTron, SANUWAVE, manufacturer). This technology has also been shown in Europe to promote healing in several wound-healing applications and is worthwhile to continue to seek the full potential of this technology in wound healing. 
Acoustic pressure waves initiate a biological response at the cellular level stimulating production of angiogenic growth factors, including endothelial nitric oxide synthase (ENOS), vascular endothelial growth factor (VEGF), and proliferating cell nuclear antigen (PCNA). These factors are important components of the normal wound healing process. This cellular activation and growth factor expression stimulated by acoustic pressure wave treatment could play a decisive role in overcoming cell quiescence and increasing growth factor titers to levels sufficient to overcome proteases. This leads to the in-growing of newly formed vessels, and the increased cellular proliferation and tissue regeneration needed to heal a wound. Clinical publications have recently reported the pressure wave induced mechanism described above can initiate and accelerate healing in burns, traumatic wounds and reconstructive skin flaps, and diabetic wounds. A pilot study using the dermaPACE device, performed in nine diabetic subjects with chronic leg ulcers has shown that this technology in patients with a history of chronic ulcers may achieve wound closure. Treatment with dermaPACE has the added benefits of being non-invasive and devoid of significant clinical side effects. Therefore, the objective of this study is to examine the safety and effectiveness of the dermaPACE acoustic pressure wave treatment device in combination with standard of care for the treatment of foot ulcers in diabetic patients. This study is intended to determine if dermaPACE offers an improved non-invasive standard of care that may shorten an otherwise lengthy healing process and therefore make later operative measures unnecessary. Given that conservative therapy may not be effective, dermaPACE may become a preferable alternative that would carry minimal risk based on the expected clinical outcomes described in this protocol. dermaPACE may improve patient quality of life when conservative therapy is not effective as well as provide a cost savings for the health care system. Criteria for Inclusion in Study Major Inclusion Criteria:
•Diabetes mellitus •One or more chronic foot ulcers (only one will be treated) that are located in the ankle area or below that has persisted a minimum of 30 days prior to the screening visit •HbA1c ‹ 12% •Diabetic Foot Ulcers › 1 cm2 and ‹ 16 cm2 •Ulcer Grade I or II, Stage A according to the University of Texas Diabetic Wound Classification system •Ankle Brachial Index (ABI) › 0.7 and ‹ 1.2, or toe pressure ›50 mmHg, or tcPO2› 40 mmHg
•Subjects on hemodialysis •Diagnosis of foot ulcer involving osteomyelitis •Has evidence of prior ulcer in the same area •Multiple diabetic foot ulcers on the foot that either are connected by fistulas or are within 5cm of the target ulcer •Subject's foot ulcer intended for study application has decreased in volume by 50% or more at the end of the two-week Run-in period as compared to the Screening visit Study Sites Locations: Arizona: Tucson Dr. Katherine Neiderer Southern Arizona VA Healthcare System Contact Phone Number 520.907.3693 Phoenix Dr. Robert G. Frykberg Phoenix VA Health Care System Contact Phone Number 602.277.5551 Phoenix and Scottsdale Dr. Arthur Tallis Hope Research Institute, LLC Contact Phone Number 602.288.4673 California: Castro Valley Dr. Alexander Reyzelman Center for Clinical Research Contact Phone Number 510.581.1484 Long Beach Dr. Ian Gordon Long Beach VA Healthcare System Contact Phone Number 562.826.5330 Sylmar Dr. Peter Balingit Olive View-UCLA Medical Center Department of Medicine Contact Phone Number 818.364.3205 Connecticut: New Haven Dr. Peter Blume North American Center for Limb Preservation Contact Phone Number 203.397.0624 Norwalk Dr. Andrew Rice Fairfield County Foot Surgeons Contact Phone Number 203.866.3377 Georgia: Atlanta Dr. Rami Calis Emory Orthpaedic and Spine Center Contact Phone Number 404.778.1566 Illinois: Chicago Dr. Robert Galiano Northwestern University Feinberg School of Medicine, Division of Plastic Surgery Contact Phone Number 312.695.6022 http://www.nmh.org/nmh/clinicaltrials/footulcer.htm Massachusetts: Boston Dr. Adam Landsman Beth Israel Deaconess Medical Center Contact Phone Number 617.632.8473 Boston Dr. Vicki Driver Boston Medical Center Contact Phone Number 617.414.6827 New York: Bronx Dr. Oscar Alvarez Center for Palliative Wound Care Contact Phone Number 718.518.2577 Ohio: Cleveland Dr. Catherine Hegarty St. Vincent's Charity Hospital Wound Care Center Contact Phone Number 440.884.1884 Columbus Dr. Gayle Gordillo Ohio State University Medical Center Contact Phone Number 614.247.6755 Texas: McAllen Dr. Joseph Caporusso Complete Family Foot Care Contact Phone Number 956.971.9107 San Antonio Dr. Robert Wunderlich Contact Phone Number 210.281.9200 Dallas Dr. Richard Galperin Contact Phone Number 214.947.4583 Wisconsin: Milwaukee Dr. Jeffrey Niezgoda Aurora Health Care Contact Phone Number 414.649.6577 International UK: London Professor Michael Edmonds Kings College Hospital Diabetic Foot Clinic Contact Phone Number (+44) 203 299 3223 Germany: Rheine Professor Maximillian Spraul Contact Phone Number 495971 46411 Reference: ClinicalTrials.gov, this record was processed on January 12, 2009. Please refer to this study by its ClinicalTrials.gov identifier: NCT00536744 |
